timothy sykes logo

Stock News

Chemours Stock Plummets Amidst Sharp EPS Decline and Market Reactions

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 2/22/2026, 8:09 am ET 2/22/2026, 8:09 am ET | 5 min 5 min read
Chemours Stock Plummets Amidst Sharp EPS Decline and Market Reactions Thumbnail

Chemours Company’s litigation over water pollution and market uncertainties have stocks trading down by -16.59 percent.

Materials industry expert:

Analyst sentiment – negative

  1. Market Position & Fundamentals: Currently, Chemours (CC) faces a mixed set of fundamental challenges. Despite generating $5.782 billion in revenue, the company struggles with profitability, as evidenced by negative profit margins (-5.69% total), affecting its valuation metrics, which show a price-to-book ratio of 8.57 and an enterprise value of $6.356 billion. Chemours carries a substantial debt load with a total debt-to-equity ratio of 14.61, which limits financial flexibility. Furthermore, return on equity is a significant concern at -69.95%, indicating underlying operational deficiencies. Nevertheless, the company maintains a revenue base, with growth observed over a five-year span at 3.33%, suggesting some resilience in its core markets.

  2. Technical Analysis & Trading Strategy: The recent price action for Chemours indicates a dominant bearish trend. Over the past week, the stock price declined from $20.71 to a close of $17.0232, signaling a breakdown below previous support levels. The rapid descent, accompanied by heavy volume, underscores a lack of short-term buying interest. For tactical traders, incorporating a short-selling strategy with a stop-loss above resistance at $18.50 is advisable, targeting the immediate support at $16.50. The sustained price rejection from higher levels and consistent lower lows provide critical evidence for continued downside potential in the near term.

  3. Catalysts & Outlook: Recent market reactions reveal significant investor concern. The sharp 19% intraday drop follows disappointing Q4 adjusted EPS, reduced from $0.09 to $0.05, falling below expectations and precipitating sales declines. These results mirror broader challenges in key segments and litigation overhangs, as noted by CFRA, which maintains a cautious stance. Benchmarking against Materials and Chemicals sectors, Chemours lags peers, with persistent headwinds overshadowing potential recoveries in sales. With heavy resistance at $18.50 and languishing under $16.50, the stock’s outlook is precarious, setting a price target of $12 as both interventional litigation and operational demand concerns persist, reflecting a neutral to negative sentiment.

Candlestick Chart

Weekly Update Feb 16 – Feb 20, 2026: On Sunday, February 22, 2026 Chemours Company (The) stock [NYSE: CC] is trending down by -16.59%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Chemours’ recent earnings report shows a sobering picture of its financial health. The adjusted earnings per share (EPS) for the fourth quarter fell to $0.05 from $0.09, not meeting the market’s $0.07 expectation. Despite slightly aligning with the $1.33 billion projection for sales, results were uninspiring. The previous high of approximately $20.71 has faded away, as prices have fluctuated significantly, closing at just over $17.

The financial metrics cast a shadow on profitability, with margins across EBIT, EBITDA, and pre-tax slightly positive but teetering near negative territories. A total debt to equity ratio of 14.61 and a leverage ratio of 25.4 point to risks from substantial borrowing. The chemical giant managed a revenue of around $5.78 billion, though recent revenues had grown just over 3% in five years, indicating limited expansion.

More Breaking News

Moreover, the cash flow isn’t paving smooth ground. The operational cash flow rests at $146 million, but negative marks in areas like deferred taxes and operating gains point to fiscal strain. With total liabilities nearing $7.27 billion, the financial strength of the company appears stretched, further emphasized by a quick ratio of 0.8, suggesting short-term liquidity challenges.

Conclusion

Chemours faces an uphill battle in restoring trader confidence amid disappointing earnings results and strategic uncertainties. The Q4 financial revelations highlight significant operational challenges that require adept management and tactical resolution. The market’s swift, adverse reaction to the earnings report reveals a deep-seated need for Chemours to strengthen its financial outlook and address lingering legal and segmental concerns.

With shares steeply declining, stakeholders must reassess their positions. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” Traders with interests in the stock would do well to adopt vigilant monitoring strategies as the company attempts to realign its business to achieve a stable growth trajectory. Chemours’ journey could hinge on effective litigation handling, debt management, and decisive actions to foster renewed market confidence.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”